Alnylam Pharmaceuticals (ALNY) Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-Ttrsc, A Subcutaneously Delivered Rnai Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis (ATTR)
4/2/2014 10:22:59 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ALN-TTRsc for designation as an orphan medicinal product for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR).
Help employers find you! Check out all the jobs and post your resume.
comments powered by